恩度胸腔灌注方案联合DP静脉化疗治疗乳腺癌恶性胸腔积液的效果分析  

Analysis of the Efficacy of Endostar Thoracic Perfusion and DP Intravenous Chemotherapy for Malignant Pleural Effusion of Breast Cancer

作　　者：范宜锋[1] 邹庆华[1] 李晓静[1] 齐秀恒[1] 董久兴 刘军[1] 王保信[1] FAN Yifeng;ZOU Qinghua;LI Xiaojing(Central Hospital of CNPC,Langfang,06500)

机构地区：[1]中国石油天然气集团公司中心医院,065000

出　　处：《实用癌症杂志》2018年第7期1175-1177,共3页The Practical Journal of Cancer

基　　金：河北省廊坊市科学技术研究与发展计划(第三批)项目(编号:2014013007c)

摘　　要：目的观察重组人血管内皮抑制素(恩度)联合化疗药物治疗恶性胸腔积液的疗效。方法选取乳腺癌所致恶性胸腔积液患者90例,根据其不同的治疗方式将其分为观察组以及对照组,每组45例。观察组应用恩度联合化疗药物治疗,对照组单独应用化疗药物治疗,治疗前均先排尽胸腔积液。治疗组在胸腹腔内注入顺铂60 mg、恩度45~60 mg;对照组除不加入恩度外,其余同治疗组。比较2组治疗效果。结果观察组的总有效率为77.78%(35/45),对照组为44.44%,组间差异有统计学意义(χ~2=5.372,P<0.05)。观察组生活质量改善率为55.26%;对照组为33.33%,组间差异有统计学意义(χ~2=4.500,P<0.05)。2组的不良反应发生率分别达到了35.56%和33.33%,差异无统计学意义(P>0.05)。治疗前,2组红细胞数无统计学差异(P>0.05);治疗后,观察组较对照组红细胞数显著减少(P<0.05)。结论对于乳腺癌所致的恶性胸腔积液采用胸腔内灌注顺铂序贯恩度治疗安全、有效,值得临床推广应用。Objective To study of the effect of endostar thoracic perfusion and DP intravenous chemotherapy for malignant pleural effusion of breast cancer. Methods 90 cases of malignant pleural effusion of breast cancer were randomly divided into the observation group and the control group according to treatment methods,45 cases in each group.The observation group was treated with endoscopy combined with chemotherapy,the control group only used chemotherapy drugs,all drainage out of the pleural effusion before treatment.The treatment group injected cisplatin 60 mg,endoscopy 45 to 60 mg;The control group except for endoscopy,and the rest were the same as the treatment group,compared therapeutic effects of the 2 groups. Results The total effective rate was 77.78%（35/45） in the observation group and 44.44% in the control group.There was significant difference between the 2 groups（χ^2=5.372, P 〈0.05）.The improvement rate of life in the observation group was 55.26% and 33.33% in the control group.There was significant difference between the 2 groups（χ^2=4.500, P 〈0.05）.The incidence of adverse reactions in the observation group and the control group were 35.56% and 33.33% respectively,the difference was not statistically significant（ P 〉0.05）.There was no significant difference in the number of erythrocytes between the 2 groups（ P 〉0.05）.After treatment,the number of erythrocytes in the observation group was significantly lower than that of the control group（ P 〈0.05）. Conclusion The thoracic infusion of cisplatin and endoscopy for patients with malignant pleural effusion caused by breast cancer is safe and effective.It is worthy of clinical application.

关 键 词：重组人血管内皮抑制素 胸腹腔积液 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]